Literature DB >> 3040579

A novel approach for the production of monoclonal antibodies using infectious vaccinia virus recombinants.

T Yilma, S S Ristow, B Moss, L Jones.   

Abstract

We describe a novel approach of producing monoclonal antibodies (MABs) to one specific protein of a virus or other agent consisting of several proteins, without the use of purified antigen in either the immunization or screening phase of the procedure. This method has general application in the production of MABs when the antigen cannot be obtained in a pure form, but the gene is available. We illustrate this application by producing MAB specific to the nucleocapsid protein (N) of vesicular stomatitis virus serotype Indiana (VSV-IN) from BALB/c mice immunized with an infectious vaccinia virus recombinant vector (v38) that expresses the N gene of VSV-IN. This novel method of immunization obviates the need for initial purification of the protein antigen and injection of adjuvants with the isolated protein as is done in traditional MAB production.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3040579     DOI: 10.1089/hyb.1987.6.329

Source DB:  PubMed          Journal:  Hybridoma        ISSN: 0272-457X


  4 in total

Review 1.  Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety.

Authors:  B Moss
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-15       Impact factor: 11.205

Review 2.  Vaccinia virus vectors: new strategies for producing recombinant vaccines.

Authors:  D E Hruby
Journal:  Clin Microbiol Rev       Date:  1990-04       Impact factor: 26.132

3.  Vaccinia virus recombinant expressing an 87-kilodalton polyprotein that is sufficient to form astrovirus-like particles.

Authors:  Rosa M Dalton; Esperanza P Pastrana; Alicia Sánchez-Fauquier
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

4.  The live vector approach-viruses.

Authors:  M Mackett
Journal:  World J Microbiol Biotechnol       Date:  1991-03       Impact factor: 3.312

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.